How drug shortages affect compounding decisions

Supply problems should be checked in FDA’s drug shortage resources for the exact product, not inferred from a retailer’s stock page. Federal compounding rules can treat shortage status differently under 503A and 503B. FDA’s shortage-compounding page explains relevant flexibility, and its broader compounding Q&A notes that some shortage-related preparations may be allowed only when conditions are met. FDA: Compounding during drug shortages FDA: Compounding and the FDA Q&A

A medicine may be hard to obtain locally even when FDA does not list it in shortage, or available locally while a national listing remains. Compounding eligibility does not turn on a patient’s anecdote alone. Ask the prescriber and pharmacy which current legal condition applies and whether an approved product can meet the medical need. A temporary enforcement policy is also different from a permanent statutory exception. FDA: FD&C Act provisions for compounding

A compounded version is not FDA-approved, even if it was made during a shortage. It may differ in form, concentration, container, instructions, and clinical evidence from an approved product. FDA identifies safety concerns with unapproved GLP-1 preparations, including labeling, shipping, and product-quality issues. Ask what exact product will be dispensed and who will answer questions if it differs from a previous refill. FDA: Concerns with unapproved GLP-1 drugs

If the shortage ends or policy changes, ask how the care plan will transition. Know whether insurance covers the approved product, whether the pharmacy can fill it, and whether the clinician needs to reassess the prescription. Keep records of the previous formulation and any effects. A shortage is a reason to make access and follow-up explicit, not a reason to buy a research-use-only material for self-treatment. AHRQ: Questions before taking medicine

If the pharmacy says it cannot obtain a prescribed product, ask whether another licensed pharmacy can fill the same approved product, what the expected delay is, and when the prescriber should be contacted. Do not assume a formulation switch is automatic. The clinician should decide whether a temporary alternative is medically appropriate and explain any new instructions. Keep a dated note of the shortage information used for the decision. FDA: Compounding during drug shortages

Shortage status can change, and a preparation made under one set of circumstances may not be appropriate to continue indefinitely. Ask how the team will know when the approved product is available again and who will review the switch. FDA’s compounding rules distinguish different facilities and conditions, so the answer should be specific to the actual pharmacy and time rather than a broad industry claim. FDA: FD&C Act provisions for compounding